Saxagliptin

CAS 361442-04-8

In Stock

Saxagliptin

Cat. No. STUB-API-SAXAGLIPTINCAS 361442-04-8In Stock

Technical Data

Cat. No.STUB-API-SAXAGLIPTIN

CAS361442-04-8

Mol. FormulaC₁₈H₂₅N₃O₂

Mol. Weight315.417 g/mol

IUPAC(1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile

SMILESC1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N

InChIInChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1

InChI KeyQGJUIPDUBHWZPV-SGTAVMJGSA-N

Purity—

Description

Overview

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic of the dipeptidyl peptidase-4 inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug

Anant Labs manufacture and furnish high quality Saxagliptin impurities for global markets. Our Saxagliptin EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.